Linear Clinical Research | Perth, Australia
Status and phase
Conditions
Treatments
About
This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally advanced or metastatic squamous Non-Small Cell Lung Cancers
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Ability to understand and be willing to sign an informed consent form
Exclusion criteria
Prior treatment with HMBD-001, docetaxel, cetuximab or any other agent that targets Epidermal Growth Factor Receptor (EGFR) or HER3, including pan-HER inhibitors
Primary purpose
Allocation
Interventional model
Masking
62 participants in 2 patient groups
Loading...
Central trial contact
Kon Yew Kwek, BMBCh, DPhil
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal